Darzalex is still the “star of the show” for Genmab
Genmab’s Darzalex royalties now cover the company’s operating costs and in addition to that, the cancer drug continues its expansion to new markets. And according to CEO, Jan van de Winkel, Genmab could potentially raise its guidance this year.
BY MARTIN HAVTORN PETERSEN
Last week, the biotech company Genmab announced its H1 results showing doubled revenue and a top line of more than DKK one billion (approximately USD 157.7 million). And once again, the driving force of the development is the myeloma drug Darzalex.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab’s cash cow obtains new approval
For abonnenter
Janssen initiates new combination study of Genmab-drug
For abonnenter
Genmab earns millions on new Darzalex approval
For abonnenter
